We have evaluated three commercial assays for collagen cross-links, two urine assays and a recently developed serum assay, as markers of bone turnover in 30 postmenopausal women with osteoporosis during their first year of treatment with the anti-resorptive drug alendronate.
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In the last decade, collagen cross-links have evolved as the most promising markers of bone resorption, and their role and limitations in the study of metabolic bone disease have recently been reviewed."? Newly formed collagen fibrils in the extracellular matrix are stabilized by crosslinks formed between the telopeptide domains of one collagen molecule and an adjacent collagen molecule. The structure of cross-links varies between the different types of collagen: crosslinks of pyridinoline (Pyr) and deoxypyridinoline (D-Pyr) structure are found in collagen types I, II, III and IX,l with D-Pyr found in the highest concentration, relative to Pyr, in bone. These post-translational modifications of collagen in bone appear to play an integral role in matrix mineralization, and are significantly different from those of other type I collagen matrices.' As neither of the pyridinolines are found in skin Correspondence: Dr P A Kyd. E-mail: a.fairney@ic.ac.uk and neither Pyr nor D-Pyr are catabolized within the body, it may be assumed that most of the Pyr and in particular D-Pyr in urine originates from bone. I This is supported by studies of Pyr excretion and bone resorption using tracer kinetics." The products of collagen degradation containing the D-Pyr and Pyr cross-links found in urine range in size from the free cross-linking amino acids to segments of the N-telopeptide and C-telopeptide sequences.! Clinical application of pyridinoline assays was initially limited by the inconvenience of the high-performance liquid chromatography (HPLC) method which used fluorescence detection after prior sample hydrolysis." A commercial antibody-based enzyme-linked immunosorbent assay (ELISA) for free D-Pyr has been developed (Dpd) which requires no pre-treatment of the urine specimen except dilution, and with less than 1% crossreactivity with free Pyr. 8 Immunoassays of the Ntelopeptide cross-linking domain of type I collagen (NTx)9 and C-telopeptide domain (CTx) in urine!" may also serve as reliable indicators of bone resorption and may have advantages over Dpd in clinical applications.'
It is now clear that bone markers have a limited role in the detection of osteoporosis, but a major application may be to monitor response to treatment.? Changes in bone markers may be demonstrated within weeks of beginning treatment, whereas changes in bone density measurements can be detected only after a minimum of 6 months to 1 year. Alendronate is an aminobisphosphonate used in the treatment of osteoporosis, reducing and to some extent correcting the bone loss in this disorder.'! Bisphosphonates are analogues of inorganic pyrophosphate, a naturally occurring inhibitor of both calcium phosphate crystal formation and dissolution in vitro. These compounds are targeted to bone by the high avidity of their P-C-P moiety for hydroxyapatite. Although the detailed mechanism of action of bisphosphonates has not been elucidated, it is clear that at the tissue level all active bisphosphonates inhibit bone resorption, bone turnover and bone IOSS. 12 The effect is due to a decrease in the generation of new bone remodelling units and a decrease in the depth of the erosion cavities. At the cellular level bisphosphonates inhibit the recruitment of osteoclast precursors and shorten the life span of osteoclasts by inducing apoptosis.':'
We have evaluated the clinical usefulness of two commercial assays for markers of bone resorption in urine (Dpd and NTx) and a recently-developed assay for CTx in serum." The objectives were to detect the suppression of bone resorption by alendronate in a group of postmenopausal women during their first year of treatment, and to determine whether the markers were predictive of changes in bone mineral density. year off treatment.'> None of the patients had abnormal liver function tests.
SUBJECTS AND METHODS

Subjects
Urine samples (second morning void) were collected at baseline and at 3-monthly intervals after beginning alendronate treatment and stored at -70°C. Serum samples at baseline, 3 and 6 months after alendronate treatment were stored at -20°C until analysis. Serial samples from each patient were analysed in the same batch.
Intra-individual variation
Normal subjects were recruited from the laboratory staff, in order to assess intraindividual variation of urine Dpd and NTx. Subjects were taking no medication, vitamins or supplements influencing bone metabolism. Each subject collected their second urine of the day between 0800 h and 1100 h.
In 11 subjects (5 men, 6 women) urine samples were collected daily for 5 days. In 10 subjects (6 men, 4 women) urines were collected at 0, I, 2, 3, 8 and 12 weeks. All urine samples from each subject were analysed in the same batch.
Intra-individual variation of serum CTx was not investigated; the assay was not available until after the intra-individual studies on urine were performed, and blood samples were not collected.
Bone densitometry
Quantitative assessment of BMD of the spine (L2-L4) and femoral neck (LUNAR DXA, Madison, USA) was performed at baseline and I year after beginning alendronate treatment. The scans were performed by two experienced operators, and analysed and computed by a single physicist; precision for normal subjects is I % at the lumbar spine and 2% at the femoral neck.
Competitive enzyme immunoassay for urine free deoxypyridinoline Free deoxypyridinoline was measured by Pyri-linksri\'-D (Metra Biosystems Inc, Mountain View, CA, USA), a commercially available ELISA, in a microwell plate format. Each urine, standard and control was first diluted I: 10 with the kit assay buffer, then added to the microwell plate which was coated with anti-Dpd, followed by addition or Dpd conjugated to alkaline phosphatase. The plate was incubated in the dark at 2-8°C for 2 h. After washing (Denley plate washer), bound alkaline phosphatase activity, inversely proportional to Dpd in the sample, was measured after a further 60 min incubation in the dark at 2G--28°C with paranitrophenylphosphate substrate. Absorbance was read at 405 nm with a microplate reader (SLT Spectra, SLT Labinstruments GmbH, Grodig, Austria). A calibration curve was constructed using the Spectra's curve-fit programme. Urine Dpd values were expressed as nanomoles per millimole creatinine. To minimize drift across the plate, the washing of the well plate was performed within 2 min, and ice cold wash buffer was used.
Competitive enzyme immunoassay for urine crosslinked N-telopeptides of type I collagen NTx was measured using an ELISA, Osteo-mark® (Ostex International, Seattle, WA, USA), which utilizes micro wells coated with NTx. No pre-dilution of urine samples is required. During incubation at room temperature for 90 min, NTx in the sample, standard or control competed with solid phase NTx for binding sites on a monoclonal anti-NTx-antibody labelled with horseradish peroxidase (HRP). After washing (Denley plate washer) bound HRP activity was measured after a further incubation with substrate/chromogen (hydrogen peroxide/tetramethyl benzidine) and addition of sulphuric acid stopping reagent. Absorbance was read at 450 nm (reference filter of 630 nm) with a microplate reader and computer-assisted data reduction was used. Urinary NTx was expressed as bone collagen equivalents (BCE) per millimole creatinine.
Competitive ELISA for C-telopeptides of type I collagen in serum Serum Cfx was measured using Serum Cross-laps@ (Osteometer BioTech A/S, Herlev, Denmark), which is based on two monoclonal antibodies against the eight amino acid sequence of the C-terminal end of the Q( chain of type I collagen. Standards, controls and samples were pipetted into streptavidin-coated microwells, followed by a mixture of biotinylated antibody and peroxidase-conjugated antibody. The sandwich complex formed between these and Crosslaps antigens then binds to the streptavidin-coated well. After incubation and washing to remove unbound antibody, a chromogenic substrate (TMB) was added. After a further incubation, the reaction was stopped with sulphuric acid and read at 450 nm in a Spectra (SLT) plate reader.
Urine creatinine
Urine creatinine was measured by a kinetic Jaffe method using the Olympus AU 5200 analyser 
RESULTS
Laboratory performance
Intra-assay precision Intra-assay precision, determined from duplicates of patient samples, was 5·0% (mean) for Dpd (manufacturer's quoted CV: 4'3-8·4%), 5·0% for NTx (manufacturer's quoted CV: 5-8%) and 5-7% for serum CTx (manufacturer's quoted CV < 5%).
Inter-assay precision
Inter-assay precision for Dpd and NTx was evaluated by measuring Low Control, High Control, and an aliquot of a low and high patient pool in each assay. Intra-assay precision for Dpd and NTx was < 10%. Inter-assay precision for Dpd and NTx was < 10%. Interassay precision for CTx, evaluated by measuring the single Control together with a low patient pool serum in each assay, was < 10%.
Clinical studies Baseline concentrations in osteoporotic patients
The baseline Dpd, NTx and CTx values before alendronate treatment are shown in personal communication), many untreated osteoporotic patients had elevated urine NTx. One patient with a very high serum CTx concentration (> 18000 pmoljL) was excluded from paired r-tests and correlations to prevent skewing the group statistics; this patient had suffered a vertebral fracture 6 weeks earlier.
There was a significant correlation between baseline Dpd and NTx (r=0-47, P<O·OI), baseline NTx and CTx (r=0'53, P<O'Ol) but the correlation between Dpd and CTx (r=0 '22) was not significant.
Intra-individual variation
The within-subject variation (CVi) of the control subjects, calculated by analysis of variance, varied over 5 days by 4-22% (mean: 9'7%) for Dpd and by 6-29% (mean: 14'5%) for NTx, and over 12 weeks by 9-25% (mean: 13'6%) for Dpd and by 5-25% (mean: 13'8%) for NTx. Intra-individual variation for serum CTx has been reported as 10·3% (mean) over 5 days and 18·7% (mean) over 2 years."
Critical difference in serial marker measurements
The critical difference is the minimal significant difference (P < 0'05) between two consecutive measurements of a quantity in the same patient.!? It is calculated by use of the following equation:
in which CD is the critical difference, CVa the analytical coefficient of variation (intra-assay CV) and CVj the within-subject biological coefficient of variation, calculated from both day-to-day variation and over 12 weeks. IS The CVa and CVj of the Dpd assay were 5·0% and 12'9%, respectively, giving a mean CD of 38·3% (95% CI: 23,2-63,0%). The CVa and CV j of the NTx assay were 5·0% and 13·8%, respectively. The CD for urine NTx is then 40·6% (20'5-69'7%). The CVa and CVj of serum CTx are 5·0% and 18·7% (over 2 years): CD for serum CTx is 53'6%, though this may be an overestimate for a lesser period of 12 weeks.
Monitoring the response to alendronate treatment Treatment with alendronate resulted in a decline at 3 months in the group mean for both NTx (-50%) and CTx (-48%), with no further significant change at 6 months (Table I) . The group mean Dpd decrease of -II % at 3 months, and -19% at 6 months was much less.
The response of individual patients to alendronate therapy is shown in Fig. 2(a) (Dpd) and 2(b) (NTx). There was no difference in the decrease of Dpd or NTx after alendronate treatment between those patients who had previously received etidronate treatment and those who had not. Using the CD calculated above (> 38% for Dpd, > 40% for NTx, > 54% for CTx) it was found that 9% (Dpd), 66% (NTx) and 60% (CTx) of individual patients showed a significant decrease after 3 months, and 23% (Dpd), 66% (NTx) and 66% (CTx) showed a significant decrease after 6 months.
Correlation of resorption markers with BMD response
After completion of the first year of treatment with alendronate there was a mean percentage increase in BMD at the lumbar spine of + 4·6% (P<O'OOI) and +3'5% (P<O·Ol) at the femoral neck. There was no significant difference between patients who were previously on etidronate and patients who were not. No significant correlation between percentage change in spine or femoral neck BMD after 1 year, or percentage change in serum CTx or urine Dpd or NTx after 6 months, was found (see Table 2 ). This suggests that bone marker response to alendronate therapy could not predict response in BMD at 1 year. A significant correlation was found for baseline Dpd and percentage change in lumbar spine BMD (P<O·Ol) alone.
DISCUSSION
The new immunoassays of pyridinium crosslinks of collagen and cross-link telopeptides are much simpler and easier to use than the original HPLC methods," making bone resorption assays widely available. However, large discrepancies have been found between different resorption assays in a variety of clinical models. [19] [20] [21] [22] [23] [24] [25] [26] Clinical application and interpretation of these immunoassays requires knowledge of the biological basis, analytical performance and clinical utility of each immunoassay. This study was carried out to evaluate the clinical usefulness of three currently available commercial kits (urine Dpd and NTx and serum CTx) in supporting patients on treatment in an osteoporosis clinic. All methods gave an acceptable intra-and inter-assay precision. The NTx assay takes less time to complete than the Dpd assay and prior dilution of urine specimens is not necessary. It has been suggested that both NTx and CTx may react generally with collagen type I peptides rather than being specific for bone collagen, since the presence of the pyridinium cross-link is not necessary for reaction with the antibody." Cross reaction of NTx with skin-derived peptides has been reported." However, it is claimed that the cross-linking domain recognized by the antibody is bone-specific since the pyridinolines formed at this site are predominantly 1%1(1) to rl2(I) and rl2(I) to rl2(I), a feature which distinguishes bone type I collagen from other tissue type I collagens.P Immunoreactive NTx has been shown to originate directly during the proteolytic cleavage of bone collagen by osteo-c1asts,29.3o rather than by degradative processes occurring later in the liver or kidney. The C-telopeptide structure is common to all tissues in which type I collagen is cross-linked by pyridinoline residues and so, theoretically, is less specific for bone."
The intra-individual variation observed for Dpd and NTx was comparable with that of previous studies. 31,32 Diurnal variation of urine CTx, Dpd and NTx has been found to be marked." making it important to take serial measurements at the same time of day. In general, serum assays show smaller intraindividual variation than urine assays. Serum assays have no requirement for adjustment of bone markers for urine creatinine concentration, eliminating a significant source of error. However, although an advantage of the serum CTx assay is the lower amplitude of diurnal variation, half that seen in urine CTx, intra-individual variation of serum CTx over long periods was only slightly better than that of urine CTX. 16 The percentage decrease found in urine NTx and serum CTx on alendronate therapy (see Table I ) was similar to that found in previous reports. 21, 24, 33 Although intra-individual variation is lower for Dpd than for NTx or CTx, more individual alendronate-treated patients showed a significant decrease in bone resorption using either urine NTx or serum CTx than using urine Dpd. This is due to the greater decrease in the cross-link peptides NTx and CTx, compared with free Dpd.
Our results are consistent with earlier reports of a much smaller decrease in urine free Dpd, compared with peptide markers NTx and CTx, in response to bisphosphonate therapy, 19, 21, 24, 35 hormone replacement therapy23,24 and calcium supplementation.P Cross-linked telopeptides of type I collagen appear to most sensitively reflect the change in bone resorption in these diverse therapies.
Randall et al,, 34 having confirmed that the response of NTx was much greater than Dpd (in monitoring the response of Paget's disease to pamidronate therapy), suggested a possible causal relationship between the bone resorption rate and the free fraction of D-Pyr. They present a model in which pyridinoline-containing fragments are sequentially degraded to free pyridinolines with a rate-limiting step in the sequence between peptide forms (as measured by NTx) and the free forms, Tobias et al. 35 confirmed that free Dpd was not significantly decreased after neridronate therapy, and observed a striking increase in the urine free/total Dpd ratio, which they concluded was due to selective changes in peptide-bound Dpd excretion. It is not clear whether this effect occurs at the site of bone resorption, or during metabolism and subsequent excretion of resorption products. The lack of free Dpd response to changes in bone resorption, whatever the cause, limits its clinical utility in monitoring response to treatment in metabolic bone disease. This is particularly relevant with the recent introduction of Dpd and other bone resorption marker applications to many automated immunoassay analysers, increasing their availability beyond specialist bone laboratories.
It has been suggested that a single measurement of biochemical bone markers may aid the detection of those at risk of osteoporosis. The baseline measurements showed that few patients with postmenopausal osteoporosis had values above the postmenopausal reference range. Bone markers should not be used to assess risk of osteoporosis as a first-line screen, or without HMO measurements.
Yearly or 2-yearly estimates of BMD impose practical difficulties in the rapidity with which responses to treatment can be evaluated. Since biochemical estimates of bone turnover can be used to predict, albeit imperfectly, rates of bone loss, the question arises whether they can be used to assess responsiveness to treatment or compliance earlier than when using density measurements. In the treatment of osteoporosis, a significant decrease of resorption marker in the individual patient after 3 or 6 months' therapy may aid their treatment by encouraging compliance in the patient and reassuring the clinician of response to therapy. In the present study, CTx and NTx were useful in demonstrating a response to alendronate in individuals after 3 months, but not in predicting the increase in BMD at either spine or hip after I year. Greenspan et al. 36 concluded that early significant decreases in NTx and serum osteocalcin in elderly women treated with alendronate for 2·5 years are associated with long-term improvement of BMD at a number of sites. Garnero et al. 21 found changes in markers of bone turnover, including D-Pyr (measured by HPLC) and NTx, after 3 months correlated significantly with changes in BMD in the lumbar spine after 2 years. Garnero et al. 22 in the EPIDOS study, found that concentrations of urine Dpd and CTx, but not NTx, were higher in untreated elderly women who went on to have hip fractures, compared with those who did not. Combining the measurement of BMD and a resorption marker may be useful in the assessment of fracture risk. In the Fracture Intervention Trial, Bauer et alY found that higher levels of NTx and bone-specific alkaline phosphatase at baseline were associated with greater increases in spine BMD, but no hip BMD, after 3 years' treatment with alendronate. In the present study only baseline Dpd was predictive of BMD response at I year, though this may change when the 2-year BMD data are completed.
Recent advances in the development of bone markers have provided assays with increased specificity, sensitivity and availability. There is particular interest in the development of serum resorption marker assays, which may have the advantages of reduced diurnal and intra-individual variation of a serum assay, and greater convenience of sample collection. Blood samples are routinely drawn for the monitoring or investigation of patients with metabolic bone diseases, so no additional sample is needed. An assay for serum type I collagen C-telopeptide developed earlier (ICTP) was found to be less sensitive than urine resorption markers in osteoporosis." We found that the newlydeveloped serum CTx assay appears to have acceptable performance characteristics, similar to those reported for the urine CTx assay, 10 and is sensitive to changes in bone turnover. Both serum CTx and urine NTx were useful in detecting an early response to therapy, perhaps Ann Clin Biochem 1999: 36 the most valid role of bone markers in individual patients." Only baseline urine Dpd was associated with the degree of improvement in BMD after I year. Further research is needed to understand the biochemical basis of the relatively poor correlation between different resorption markers, and the differences in their response to anti-resorptive therapies.
